Twist Bioscience (NASDAQ:TWST) Given New $50.00 Price Target at Evercore ISI

Twist Bioscience (NASDAQ:TWST) had its price objective upped by Evercore ISI from $46.00 to $50.00 in a research note published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock.

Several other brokerages have also recently issued reports on TWST. The Goldman Sachs Group raised Twist Bioscience from a neutral rating to a buy rating and increased their price objective for the stock from $25.00 to $45.00 in a research note on Wednesday, January 17th. Barclays upped their price objective on Twist Bioscience from $40.00 to $45.00 and gave the stock an overweight rating in a research note on Friday. Robert W. Baird upped their target price on Twist Bioscience from $39.00 to $40.00 and gave the company an outperform rating in a research report on Friday. Finally, Scotiabank upped their price target on shares of Twist Bioscience from $30.00 to $43.00 and gave the company a sector outperform rating in a research note on Monday, February 5th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Twist Bioscience presently has a consensus rating of Buy and a consensus target price of $41.67.

Twist Bioscience Trading Up 28.7 %

TWST stock traded up $9.20 during midday trading on Friday, reaching $41.21. 4,458,430 shares of the company traded hands, compared to its average volume of 909,964. The business has a 50 day moving average of $34.03 and a 200-day moving average of $30.96. Twist Bioscience has a 52-week low of $11.81 and a 52-week high of $43.21.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 30.81%. The business’s revenue was up 25.1% on a year-over-year basis. During the same quarter last year, the business earned ($1.06) EPS. Research analysts predict that Twist Bioscience will post -3.17 earnings per share for the current year.

Insider Buying and Selling at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the sale, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, CEO Emily M. Leproust sold 1,128 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total value of $37,810.56. Following the transaction, the chief executive officer now directly owns 515,281 shares of the company’s stock, valued at approximately $17,272,219.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Patrick John Finn sold 2,174 shares of the firm’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $30.12, for a total value of $65,480.88. Following the completion of the transaction, the chief operating officer now owns 176,206 shares in the company, valued at approximately $5,307,324.72. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,211 shares of company stock worth $449,573. Company insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Hedge funds have recently made changes to their positions in the company. Federated Hermes Inc. acquired a new position in Twist Bioscience in the third quarter valued at about $29,000. China Universal Asset Management Co. Ltd. boosted its holdings in Twist Bioscience by 96.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience in the 4th quarter valued at $30,000. Allspring Global Investments Holdings LLC grew its stake in Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock worth $70,000 after buying an additional 1,179 shares during the last quarter. Finally, International Assets Investment Management LLC boosted its holdings in shares of Twist Bioscience by 3,519.8% in the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock valued at $148,000 after acquiring an additional 3,907 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.